Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer. Click here to learn more.
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer. Click here to learn more.
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02). Click here to learn more.